
COVIDã¯ã¯ãã³ãçç¶ã®ãªã人ã§ãé·æçãªå¿èé害ãåŒãèµ·ããå¯èœæ§
å èšäºã¯ãã¡ããã/Click here to read the original article.
æ¥æ¬ã®ç ç©¶è ãã¡ã¯ãCOVID-19ã¯ã¯ãã³ãæ¥çš®ãã人ã -ç¡çç¶ã®æ£è ãå«ã-ã«é·æã«ãããå¿èé害ã®èšŒæ ãèŠã€ãã£ããšçºè¡šããããã®ç¥èŠã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã«å¿ççãçºçãã人ã®ã»ãšãã©ã¯çç¶ãåºããããããã«è¯ããªãããšããçŸç 察çäºé²ã»ã³ã¿ãŒã®äž»åŒµãšççŸãããã®ã§ããã
æ¥æ¬ã®ç ç©¶è ãã¯ãã¯ã¯ãã³ã«ããå¿ççã¯ãŸãã§ãäžéæ§ã§ãããå¿èã®çç¶ããã人ã«éããããšèããããŠããã«ãããããããCOVID-19ã¯ã¯ãã³ãæ¥çš®ãã人ïŒç¡çç¶ã®æ£è ãå«ãïŒã«é·æã«ãããå¿èé害ã®èšŒæ ãèŠã€ãã£ããšçºè¡šããã
å¹Žéœ¢ãæ§å¥ã«é¢ä¿ãªããç»å蚺æã®180æ¥åãŸã§ã«2åç®ã®ã¯ã¯ãã³æ¥çš®ãåããæ£è ã¯ãã¯ã¯ãã³æªæ¥çš®è ã«æ¯ã¹ãŠãç»å蚺æè¬ã§ããããçŽ -18ãã«ãªãããªãã·ã°ã«ã³ãŒã¹ïŒFDGïŒã®å¿èçµç¹ãžã®åã蟌ã¿ã47ïŒ é«ãã£ãã
FDGã¯äœå ã®äž»èŠãªãšãã«ã®ãŒæºã§ããç³ã§ããã°ã«ã³ãŒã¹ãšåããã®ã§ããããããçŽ ã®æŸå°æ§åœ¢æ ã§ããããçŽ 18ãå«ãã§ãããFDGãéç©ããèåšãçµç¹ã®ç»ååãå¯èœã§ããã
å¿ççã®ç¹åŸŽã§ããã¹ãã¬ã¹ãæå·ãåãã现èã¯ãå¥åº·ãªçްèãããå€ãã®ã°ã«ã³ãŒã¹ãåã蟌ãã
æ ¶æçŸ©å¡Ÿå€§åŠå»åŠéšã®äžåäžåæ°çããç ç©¶è ãã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®åïŒ2020幎11æ1æ¥ïœ2021幎2æ16æ¥ïŒã«ç»å蚺æãåããæ£è ãšãã¯ã¯ãã³æ¥çš®åŸïŒ2021幎2æ17æ¥ïœ2022幎3æ31æ¥ïŒã«ç»å蚺æãåããæ£è ãšã®éã§ãããžããã³æå±€æ®åœ±ïŒã³ã³ãã¥ãŒã¿æå±€æ®åœ±ïŒPET/CTïŒã¹ãã£ã³ãæ¯èŒããåŸãåãç ç©¶ãã¶ã€ã³ãçšããã
SARS-CoV-2ã¯ã¯ãã³æ¥çš®è 700äººãæªæ¥çš®è 303人ã®èš1,003人ãã幎霢ïŒ40æ³æªæºã41ïœ60æ³ã60æ³ä»¥äžïŒãæ§å¥ãã¯ã¯ãã³æ¥çš®ããPET/CTãŸã§ã®æéã§ã°ã«ãŒãåãããã
ã¯ã¯ãã³æ¥çš®ãåãã被éšè ã®ãã¡ã78ïŒ ã¯ãã¡ã€ã¶ãŒãã€ãªã³ããã¯ç€Ÿã®BNT162b2補å€ãæ¥çš®ããã21ïŒ ã¯ã¢ãã瀟ã®mRNA補å€ãæ¥çš®ããããFDGã®åã蟌ã¿ã«å·®ã¯èªããããªãã£ãã
ã¢ã¹ãã©ãŒãã«ã®äºé²æ¥çš®ãåãã被éšè ããŸãã¯ä»ã®äžè¬çã§ãªãã¯ã¯ãã³ãåãã被éšè ã¯ãæ°ãå°ãªããšè§£æã«äžç¢ºå®æ§ãçããããé€å€ãããã
ç¡çç¶ã®è¢«éšè ã®ã¿ããå®å šæ§ã®ã·ã°ãã«ãæããããããç ç©¶è ãã¯å¿èã«é¢ä¿ã®ãªãåé¡ã§ã¹ãã£ã³ãåãã被éšè ãéžãã ãã»ãšãã©ã®æ€æ»ã¯ç蚺æã®ããã®ãã®ã§ãã£ãã
FDGã®é«ãåã蟌ã¿ã¯ãèèãèŸèãå šèº«ãå«ãå¿è以å€ã®çµç¹ãç¹ã«è 窩ïŒããã®äžïŒãªã³ãç¯ã§ã芳å¯ãããã以åã®ç ç©¶ã§ã¯ããããã®å¹æã¯2-3é±éã§æ¶å€±ãããšãããŠããããäžåæ°ã¯6ãµæéæç¶ããããšã瀺ããã
25人ã®è¢«éšè ãçæ¹ãŸãã¯äž¡æ¹ã®è©Šéšæéäžã«2å以äžã®ã¹ãã£ã³ãåãã16人ã¯ã¯ã¯ãã³æ¥çš®åãšæ¥çš®åŸã®äž¡æ¹ã®æéã«PET/CTæ€æ»ãåããããã®å°ããªãµãã°ã«ãŒãã®äžã§ãã¯ã¯ãã³æ¥çš®ãåãã被éšè ã¯ãå¿èãšè 窩ãªã³ãç¯ã®äž¡æ¹ã§ææã«é«ãFDGåã蟌ã¿ã瀺ããã
å¿ççã¯120æ¥ä»¥äžæç¶ãããããã®æç¹ä»¥éã§ã¯çµ±èšçã«ææã§ã¯ãªãã£ãã
å¿ççã¯äžè¬éå£ã§ã¯ç·æ§ã§10äžäººåœãã6.1人ã女æ§ã§4.4人ã®å²åã§çºçãããçç¶ã¯èžçãæ¯åããåæžãªã©ã§ããã
ç±³åœçŸç äºé²ç®¡çã»ã³ã¿ãŒïŒCDCïŒã«ãããšããCOVID-19ã¯ã¯ãã³æ¥çš®åŸã«å¿ççãŸãã¯å¿èçãèµ·ãããæ£è ã®ã»ãšãã©ã¯ãè¬ãšå®éã«ããåå¿ããããã«è¯ããªã£ããããšããã
å¿ççã®æ²»çã«ã¯ãå®éãé®çå€ãæççå€ããããŠå Žåã«ãã£ãŠã¯å ¥é¢ãå¿ èŠã§ããã
èè ãã¯ç ç©¶ã®éçãšããŠæ¬¡ã®3ç¹ãæããŠããã
äžåæ°ãšå ±èè ãã¯ãè§£æã®éçãšããŠ3ç¹ãæããŠããã
第äžã«ããã®ç ç©¶ã¯åäžã®ç é¢ã§ã®åŸæ¹èŠçç ç©¶ã§ããã被éšè ã®å¥åº·ç¶æ ã代è¬ãã³ã³ãããŒã«ããèœåãéãããŠãããããå¿ççãäºæž¬ããåã¯éãããŠããããã®ãããèè ãã¯æ¬¡ã®ããã«çµè«ã¥ããïŒ ãå¿é µçŽ å€ãå¿æ©èœãéRNAã¯ã¯ãã³æ¥çš®ãšã®æ¯èŒãå«ããæ¬ç ç©¶ã®çµæãæ€èšŒããããã«ã¯ãååãç ç©¶ãå¿ èŠã§ããããã
第2ã«ãã¹ãã£ã³çµæã¯éå»ã®èšé²ããåŸããããã®ã§ãã£ããããç ç©¶è ãã¯FDGå¿èæ€æ»ã®ããã«è¢«éšè ãé©åã«æºåããããšãã§ããªãã£ããFDGã¯é£åç³ãšåæ§ã«èç©ã»ä»£è¬ããããããFDGæ®åœ±ãåãã被éšè ã¯éåžžãæ€æ»ãŸã§ã®éãçµ¶é£ãŸãã¯ç¹å¥ãªé£äºããšããäžåæ°ã¯æ€æ»åã®æºåã«ã€ããŠã³ã³ãããŒã«ã§ããªãã£ãã
第äžã«ãFDGæ€æ»ã¯å¿ççãè©äŸ¡ããããã«ç¹å¥ã«è¡ãããããã§ã¯ãªãã
ãŠã£ã¹ã³ã³ã·ã³å€§åŠå»åŠéšããã³å ¬è¡è¡çåŠéšã®å¿èè¡ç®¡ç»å蚺æã®å°éå®¶ã§ããDavid Bluemkeå»åŠå士ã¯ãåèªã®åãå·ã«æ²èŒãããè«è©ã®äžã§ãæ¥æ¬ã®ç ç©¶è ã®æèŠã軜èŠããçµæãäžæ¹ä¿®æ£ããå¯èœæ§ã®ããä»ã®2ã€ã®æ¬ é¥ãææããã
Bluemkeæ°ã¯ãäžåæ°ã®è¢«éšè ã®çµã¿å ¥ãåºæºã¯ãã䟿å®çãªãµã³ãã«ããã€ãŸãæãŸããçµæãåŸãããã«ãªãŒããŒã¡ã€ãããããµã³ãã«ã§ãããšè¿°ã¹ãã圌ã¯ãFDGã®å¿èãžã®åã蟌ã¿ãé«ãã®ã¯ãããæ£è ã«ãšã£ãŠã¯æ£åžžãªããšã§ãããã¯ã¯ãã³æ¥çš®ã®çµæã§ã¯ãªããšäž»åŒµããã
ãããã圌ã®äž»ãªæ¹å€ã¯FDGå¿èã¹ãã£ã³ã®éçã«çŠç¹ãåœãŠããã®ã§ãã£ãããæ®å¿µãªãããæ¥åžžèšåºã«ãããŠã18F FDG PET/CTã¯å¿çã®ççãè©äŸ¡ãããã¬ãŒãµãŒãšããŠã¯ææªã§ãããã«ãŒãã³ã®PET/CTã§ã¯ãæ£åžžå¿çã®ããã¯ã°ã©ãŠã³ããæ¢ã«é«ãç¶æ ã§ãççã«ããé«ã掻æ§ã確å®ã«åå®ããããšã¯ã§ããªããã
ãä»ã泚å°ãæã£ã人ã§å¿èãæ£åžžãªäººã¯ã»ãšãã©ããªãã
ãããããã¹ãŠã®ã³ã¡ã³ã¿ãŒãæççã ã£ãããã§ã¯ãªãã
å¿èå°éå»ã§COVID-19ã¯ã¯ãã³æ¥çš®ã®æ¹å€è ã§ããããŒã¿ãŒã»ããã«ããŒå士ã¯ãZeee Mediaã®ãªã³ã©ã€ã³ã»ã€ã³ã¿ãã¥ãŒã§äžåç ç©¶ã«ã€ããŠã³ã¡ã³ãããã
ããã«ããŒæ°ã¯ãã¢ã¹ãªãŒããå«ãè¥è ã®å¿åæ¢ãèšé²çãªæ°ã«ãªã£ãŠããããšãææããããã®ã»ãšãã©ã®çäŸã§åæ€æèŠã¯æ£åžžã§ããã«ããããããããå¿èã«äœãåé¡ãããããšåœŒã¯è¿°ã¹ãã
ããã«ããŒã¯Zeee Mediaã«ããèªã£ãïŒ
ãäžåæ°ãã«ãããã®ç»æçãªè«æã¯ããã®çãã®å€ããåããŠãããŸãããéœé»åæŸå°æå±€æ®åœ±ã¯ãå¿èã®ç å€éšãæ¢ããšãã«ç§ãè¡ãæ€æ»ã§ããéåžžãPETã¹ãã£ã³ã¯è¡æµãååã§ãªãããããã¯ç çãªé åã§éœæ§ãšãªããŸãã
ããã«ããŒã¯ã人éã®å¿èã¯çææºãšããŠéé¢èèªé žãå¿ èŠãšãããšèª¬æãããã°ã«ã³ãŒã¹ã奜ãããã«å€åããå¿ç现èã¯ãä»£è¬æ©èœé害ãç æ°ã®ã·ã°ãã«ã§ããã
ãäžåãå ±åããã®ã¯ãCOVID-19ã¯ã¯ãã³ãæ¥çš®ããã»ãŒãã¹ãŠã®äººã«ã€ããŠãå¿èãéé¢èèªé žãããã°ã«ã³ãŒã¹ã奜ãããã«ãªã£ããšããããšã§ãããšããã«ããŒã¯èšãããããŠFDGã圌ãã®å¿èã ãã¯ãªã¹ãã¹ããªãŒã®ããã«ãç §ãããã®ã§ããããããCOVID-19ã¯ã¯ãã³ãæ¥çš®ããªãã£ã人ã®PETã¹ãã£ã³ã¯æ£åžžã§ãã£ãããã«ãã©ã¯6ãµæåŸãŸã§æ£è ã調ã¹ãããå€åã¯ãŸã ãã£ãã
ãã®ãã¡ãŒãžãæ°žä¹ çãªãã®ãã©ãããšãã質åã«å¯ŸããŠãããã«ããŒã¯ããããããŸãããããããä»èšããããšã¯ãäºé²æ³šå°ãæã£ã人ã§ãšããã·ã§ã³æå±€æ®åœ±ã§å¿èãæ£åžžãªäººã¯ã»ãšãã©ããªããšããããšã§ãã
ããã«ããŒã¯ãã¯ã¯ãã³æ¥çš®åŸ9ã¶æã§å¿èã«é害ãèŠã€ãã£ããšããç ç©¶ããæ°žä¹ çãªå¿èé害ã®ãªã¹ã¯ã¯ã¯ã¯ãã³1åã«ã€ãçŽ2.5ïŒ ã§ããããšã瀺åããä»ã®ç ç©¶ãåŒçšããã
ããã«ããŒã®èšåºçµéšããããã®ç¥èŠãšäžèŽããŠããã圌ã¯ãå¿èã®äž»èŠãªãã³ã宀ã§ããå·Šå¿å®€ã®å°ããªæå·éšäœã¯ãæéã®çµéãšãšãã«ãéåžžã¯1幎以äžã®æ²»çã§æ¶å€±ãããã15ïŒ ä»¥äžã®æå·ã¯æ¶å€±ããªããšå ±åããŠããã
ãäžè¬çã«ãå·Šå¿å®€ã®15ïŒ ä»¥äžãå¿ççã«äŸµããããšãå¿åæ¢ã®ãªã¹ã¯ãæ¥äžæããŸããã
VAERSã®éå°å ±åã¯èª€ã£ãæšæž¬ãçã
Bluemekeæ°ã¯ãç±³åœã®ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒãã¯ã¯ãã³ã«é¢é£ãããã¹ãŠã®å·å®³ãæ£ç¢ºã«ææããŠãããšããä»®å®ã«åºã¥ããŠè«è©ãè¡ã£ãã
圌ã¯ã2021幎12æãŸã§ã«VAERSã«ã¯ãã¯ã¯ãã³æ¥çš®åŸ7æ¥ä»¥å ã«çºçããå¿ççã®å ±åçäŸã1626ä»¶å«ãŸããŠããããšæžããŠãããããã¯mRNAã¯ã¯ãã³10äžåæ¥çš®ã«å¯ŸããŠå¿ççã®çºççã7ïœ11ä»¶ã§ããããšãæå³ããŠããã
Bluemkeæ°ã«ãããšããã®å¿çççºççã¯åŸã«ç·æ§10äžäººããã8ïœ27ä»¶ã«ä¿®æ£ããã2021幎3æã®ç ç©¶ã§ããã®åæšå®ã確èªãããã
ããããVAERSããã¹ãŠã®ããããã¯ã»ãšãã©ã®ã¯ã¯ãã³ã®å¯äœçšãèšé²ããèœåã«çåãæããããããŠããã2023幎11æã®British Medical Journalã®è«èª¬ã¯æ¬¡ã®ããã«ææããŠããïŒ
ãVAERSã¯ãŠãŒã¶ãŒãã¬ã³ããªãŒã§ãè¿ éã§ãéææ§ã®é«ããã®ã§ããã¹ãã ãããããBMJèªã®èª¿æ»ã«ãããVAERSã¯ãã®åºæºãæºãããŠããªãããšãæããã«ãªã£ããã³ããã¯ã¯ãã³ã®çºå£²ä»¥æ¥ãåäŸã®ãªãå ±åæ°ã«ã¹ã¿ããã®ã¬ãã«ã远ãã€ããŠããªãã ãã§ãªããã·ã¹ãã ã«è² æ ãããããå ±åããã©ããŒã¢ããããããã·ã°ãã«ãèŠéãããŠããå åããããã
7æã«æåºããã2020幎æ«ã®ç ç©¶ã§ããããããã³ãããã¯ãå§ãŸãåãå§ãŸã£ãé ã«æžããããšæãããããVAERSã«ããã¯ã¯ãã³æäžåŸã®ã¢ããã£ã©ãã·ãŒïŒçåœãè ããé節ãªå ç«åå¿ïŒã®ææçã¯æ¥åžžçã«12-24ïŒ ã®ç¯å²ã§ãã£ããšå ±åãããŠãããã€ãŸãã8ä»¶ã«7ä»¶ãã®çäŸãå ±åãããŠããªãã®ã§ããã
ã³ãã³ãã¢å€§åŠã®ç¥çµç§åŠè ã¹ããã»ãã³ã¿ã¶ãã¹å士ïŒåœæïŒã«ãã2021幎10æã®ãã¬ããªã³ãåæã«ããã°ããVAERSã«ããæ»äº¡å ±åã¯20åã®1ã§ãããVAERSã®éå°ç¢ºèªãã€ã¢ã¹ãšäžèŽããŠããããã³ã¿ã¶ãã¹æ°ã¯ããCOVIDã¯ã¯ãã³ãšããŒã¹ã¿ãŒã®ãªã¹ã¯ã¯ãå°å ãè¥å¹Žæäººãé«éœ¢è ã§è·æ¥äžã®ãªã¹ã¯ãäœãããããã¯éå»ã«ã³ãããŠã€ã«ã¹ã«æŽé²ãããããšã®ãã人ã«ãããŠã¯ããããã£ãããäžåã ããšçµè«ã¥ããã
ãã³ã¿ã¶ãã¹ãã³ãã³ãã¢ã®æè·å¡ã§ãããã©ããã¯äžæã§ãããè«æã®çºè¡šç¶æ³ãäžæã§ãããã³ãã³ãã¢ã®ç¥çµç§åŠã®ãŠã§ãããŒãžã«ã¯ãã³ã¿ãµãã¹æ°ã®ååãããããcolumbia.eduã®ã¢ãã¬ã¹ã«ã¡ãŒã«ãéã£ãŠãããŠã³ã¹ããŠããŸãããã³ã¿ã¶ãã¹ã¯æè¿ãã©ãŠã³ã¹ããŒã³ã»ã€ã³ã¹ãã£ãã¥ãŒãã«æå±ããŠãããã圌ã®äž»ãªæå±ã¯ã³ãã³ãã¢å€§åŠå©ææã®ãŸãŸã§ããã
2023幎9æ12æ¥ã®æç¹ã§ãCDCã¯COVID-19ã¯ã¯ãã³æ¥çš®åŸã®ã¢ããã£ã©ãã·ãŒçºççã¯100äžåæ¥çš®ã®ãã¡ããã5åã§ãã£ããšå ±åããŠããã
ææ°ã®VAERSããŒã¿ã«ãããšã2020幎12æ14æ¥ãã2023幎10æ27æ¥ã®éã«ãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã«å¿ççïŒå¿èçã26,366äŸå ±åãããŠãããå¿çæ¢å¡ã®å ±åã5,385ä»¶ãã£ãã